Gila Therapeutics, Inc.
Minneapolis, US · Founded 2014 · Delaware corporation · 3 known investors
Gila Therapeutics is a clinical-stage biotech company developing topical/lingual hormone therapies (starting with Topical Lingual PYY) that activate satiety centers in the brain via a tongue-brain neural pathway without systemic exposure. Its treatments target obesity, type 2 diabetes, and associated cardiometabolic disorders.
BiotechDigital HealthLongevity
Founders & leadership
CD
Christopher de SouzaDirector
TJ
Thomas J. VasicekExecutive Officer, Director, Promoter
JF
Jon FreemanExecutive Officer
RH
Richard HoranDirector
DR
Donald R. JohnsChief Medical Officer
Investors · 3
Reported raises · per SEC filings
Form D private placements▶$399.6KraisedDec 2023 · 7 investors · BiotechnologyRule 506(b)
▶$399.6KraisedDec 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy BarberichDirector
- Christopher De SouzaDirector
- Praveen TyleDirector
- Jon FreemanExecutive Officer
- Thomas VasicekExecutive Officer
- Richard HoranDirector
- Scott SchorerExecutive Officer, Director
- Sangeeta KashyapExecutive Officer
- Offering amount
- $10M
- Amount sold
- $399.6K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$355.5KraisedNov 2022 · 6 investors · BiotechnologyRule 506(b)
▶$355.5KraisedNov 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- SCOTT SCHORERExecutive Officer, Director
- TIMOTHY BARBERICHDirector
- CHRISTOPHER DE SOUZADirector
- JON FREEMANExecutive Officer
- RICHARD HORANDirector
- Offering amount
- $5M
- Amount sold
- $355.5K
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedNov 2021 · 28 investors · BiotechnologyRule 506(b)
▶$1.3MraisedNov 2021 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard HoranDirector
- Christopher de SouzaDirector
- Scott SchorerExecutive Officer, Director
- Thomas VasicekExecutive Officer
- Jon FreemanExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$314.4KraisedMar 2019 · 3 investors · BiotechnologyRule 506(b)
▶$314.4KraisedMar 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard HoranDirector
- Thomas J. VasicekExecutive Officer, Director, Promoter
- Christopher de SouzaDirector
- Jon FreemanExecutive Officer
- Offering amount
- $2M
- Amount sold
- $314.4K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$3.3MraisedApr 2017 · 33 investors · BiotechnologyRule 506(b)
▶$3.3MraisedApr 2017 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher DeSouzaDirector
- Andres AcostaPromoter
- Richard HoranDirector
- Jon FreemanExecutive Officer
- Sergei ZolutukhinPromoter
- Thomas J. VasicekExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $3.3M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$500KofferedFeb 2017 · BiotechnologyRule 506(c)
▶$500KofferedFeb 2017 · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Christopher de SouzaDirector
- Thomas J. VasicekExecutive Officer, Director, Promoter
- Andres AcostaPromoter
- Jon FreemanExecutive Officer
- Richard HoranDirector
- Sergei ZolutukhinPromoter
- Offering amount
- $500K
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.